India's Aurobindo Pharma down after US FDA flags serious concerns at facility
15/06/2026 06:23
BUZZ-India's Aurobindo Pharma down after US FDA flags serious concerns at facility ** Shares of India's Aurobindo Pharma ARBN.NS down 1.3% to 1,453.8 rupees, snapping a three-session winning streak
** Stock set for biggest percentage fall since May 27, if losses hold
** US FDA on Friday flagged inspection classification of subsidiary's facility in Telangana as "official action indicated" - most serious FDA inspection classification
** Regulator concluded the inspection with 11 observations, co said
** ARBN noted it is committed to maintaining quality manufacturing standards across all facilities
** YTD, stock up 12.47%
(Reporting by Saikeerthi in Bengaluru)
((Saikeerthi@thomsonreuters.com; (+91) 8296756080))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11